NR2E1

Nuclear receptor subfamily 2 group E member 1 · Q9Y466 · NR2E1 on Sugi Atlas →

15,638 patent compounds predicted against NR2E1, 10,821 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL574115	0.80	20/20
SCHEMBL589390	1.00	19/20
SCHEMBL706770	0.61	19/20
SCHEMBL396514	0.64	15/20
SCHEMBL827379	0.47	14/20
SCHEMBL574587	0.49	7/20
SCHEMBL573468	0.48	7/20
SCHEMBL896467	0.74	6/20
Hydrochloric Acid (SCHEMBL896128)	0.73	6/20
SCHEMBL828849	0.48	6/20
SCHEMBL343455	0.41	6/20
Propranolol (SCHEMBL3955)	1.00	5/20
Levopropranolol (SCHEMBL3956)	1.00	5/20
Dexpropranolol (SCHEMBL25255)	1.00	5/20
SCHEMBL773269	1.00	5/20
Propranolol (SCHEMBL41688)	0.97	5/20
Levopropranolol (SCHEMBL41689)	0.97	5/20
Dexpropranolol (SCHEMBL610656)	0.97	5/20
Dexpropranolol (SCHEMBL614105)	0.95	5/20
Propranolol (SCHEMBL614322)	0.95	5/20

Clinical trials — most relevant to NR2E1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Chronic Effects of Estrogen in Microcirculation	PHASE4	COMPLETED
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women	PHASE3	COMPLETED
Effect of Metformin in Children With Type 1 Diabetes	PHASE2/PHASE3	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Fibrates in Pediatric Cholestasis	PHASE2	COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease	PHASE2	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Preoperative Bexarotene Treatment for Cushing's Disease	PHASE1/PHASE2	UNKNOWN
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B.	nan	UNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
RORC Genetic Polymorphism of Rheumatoid Arthritis	nan	COMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer	nan	COMPLETED
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Comparison of Salivary Biormarkers Levels With Periodontal Clinical Parameters in Smokers and Non-Smokers With Different Periodontal Diseases	nan	COMPLETED
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions	nan	UNKNOWN
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease	nan	COMPLETED
Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients	nan	COMPLETED
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone	nan	COMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis	nan	COMPLETED
Study of Biomarkers in Tissue Samples From Patients With Breast Cancer	nan	UNKNOWN
Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?	nan	UNKNOWN
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NR2E1 binder may also engage these)

Protein	Name	Similarity
Q9YGL3	—	1.000	Q9YGL3 →
Q91379	—	1.000	Q91379 →
Q06725	—	1.000	Q06725 →
Q64104	—	1.000	Q64104 →
Q6PH18	—	1.000	Q6PH18 →
Q9TTR8	—	1.000	Q9TTR8 →
NR2F2	COUP transcription factor 2	1.000	landscape →
Q90733	—	0.998	Q90733 →
F1QLY4	—	0.998	F1QLY4 →
Q9TTR7	—	0.998	Q9TTR7 →
P28700	—	0.998	P28700 →
Q90415	—	0.998	Q90415 →
P51129	—	0.998	P51129 →
Q9TU15	—	0.997	Q9TU15 →
P51448	—	0.997	P51448 →
P70052	—	0.997	P70052 →
Q7SYN5	—	0.997	Q7SYN5 →
Q28037	—	0.996	Q28037 →
Q06726	—	0.996	Q06726 →
P10589	—	0.996	P10589 →
Q90416	—	0.996	Q90416 →
RXRA	Retinoic acid receptor RXR-alpha	0.996	landscape →
P43135	—	0.996	P43135 →
P51128	—	0.996	P51128 →
O09018	—	0.995	O09018 →
ESRRB	Steroid hormone receptor ERR2	0.995	landscape →
P06212	—	0.995	P06212 →
Q6GN21	—	0.995	Q6GN21 →
Q60632	—	0.995	Q60632 →
VDR	Vitamin D3 receptor	0.995	landscape →